- Home
- BKE vs HCM Comparison
BKE vs HCM Comparison
Compare BKE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- HCM
- Stock Information
- Founded
- BKE 1948
- HCM 2000
- Country
- BKE United States
- HCM Hong Kong
- Employees
- BKE N/A
- HCM N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- BKE Consumer Discretionary
- HCM Health Care
- Exchange
- BKE Nasdaq
- HCM Nasdaq
- Market Cap
- BKE 3.0B
- HCM 2.6B
- IPO Year
- BKE 1992
- HCM N/A
- Fundamental
- Price
- BKE $57.70
- HCM $14.40
- Analyst Decision
- BKE Hold
- HCM Sell
- Analyst Count
- BKE 1
- HCM 1
- Target Price
- BKE $55.00
- HCM $13.75
- AVG Volume (30 Days)
- BKE 476.0K
- HCM 36.7K
- Earning Date
- BKE 11-21-2025
- HCM 08-07-2025
- Dividend Yield
- BKE 6.80%
- HCM N/A
- EPS Growth
- BKE 3.79
- HCM N/A
- EPS
- BKE 4.09
- HCM 0.53
- Revenue
- BKE $1,277,894,000.00
- HCM $602,197,000.00
- Revenue This Year
- BKE $7.09
- HCM N/A
- Revenue Next Year
- BKE $2.91
- HCM $15.49
- P/E Ratio
- BKE $14.03
- HCM $5.31
- Revenue Growth
- BKE 4.67
- HCM N/A
- 52 Week Low
- BKE $33.12
- HCM $11.51
- 52 Week High
- BKE $61.69
- HCM $19.50
- Technical
- Relative Strength Index (RSI)
- BKE 58.62
- HCM 37.64
- Support Level
- BKE $52.08
- HCM $14.00
- Resistance Level
- BKE $56.82
- HCM $14.42
- Average True Range (ATR)
- BKE 1.55
- HCM 0.30
- MACD
- BKE 0.08
- HCM -0.06
- Stochastic Oscillator
- BKE 88.04
- HCM 25.34
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.